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IMPORTANCE Head and neck cancer (HNC) and its treatment may negatively alter
neurocognitive and speech functioning. However, the prevalence of neurocognitive
impairment among patients with HNC before treatment is poorly studied, and the association
between neurocognitive and speech functioning is unknown, which hampers good
interpretability of the effect of HNC treatment on neurocognitive and speech function.
OBJECTIVES To document neurocognitive functioning in patients with HNC before treatment
and to investigate the association between neurocognitive and speech functioning.
DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of newly diagnosed patients
with HNC before treatment using a large sample obtained in a nationwide, multicenter setting
(Netherlands Quality of Life and Biomedical Cohort Study in Head and Neck Cancer
[NET-QUBIC] project).
MAIN OUTCOME ANDMEASURES Objective neuropsychological measures of delayed recall,
letter fluency, and executive functioning, as well as patient-reported outcomemeasures on
neurocognitive speech and functioning, were collected before treatment.
RESULTS In total, 254 patients with HNC participated (71.7%male), with a mean (SD) age of
62 (10) years. The response rate ranged from 81.9% (208 of 254) to 84.6% (215 of 254).
Objective neurocognitive measures indicated that 4.7% (10 of 212) to 15.0% (32 of 214) of
patients were initially seen with moderate to severe cognitive impairment. Mild to moderate
impairment was found in 12.3% (26 of 212) to 26.2% (56 of 214) of patients. Themost altered
domains were delayed recall and letter fluency. Seven percent (15 of 208) of the patients
reported high levels of everyday neurocognitive failure, and 42.6% (89 of 209) reported
speech problems. Objective neurocognitive function was not significantly associated with
patient-reported neurocognitive or speech functioning, but the results from patient-reported
outcomemeasures were significantly correlated.
CONCLUSIONS AND RELEVANCE Results of this study demonstrate a high prevalence of
impaired speech functioning among patients with HNC before treatment, which is in line with
previous findings. A novel finding is that neurocognitive impairment is also highly prevalent
as objectively measured and as self-perceived. Understanding the reason why patients with
HNC are initially seen with neurocognitive impairment before the start of treatment is
important because this impairment may complicate patient-clinician interaction and alter
treatment adherence and because treatment itself may further worsen cognitive functioning.
In addition, low self-perceived neurocognitive and speech functioning before treatment may
decrease a patient’s confidence in communicative participation and perceived quality of life.
Disentangling the associations between objective and patient-reported neurocognitive and
speech functions is an important area for future research.
JAMA Otolaryngol Head Neck Surg. 2019;145(3):251-257. doi:10.1001/jamaoto.2018.3981
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B eing able to communicate is an important factor thatpredictsqualityof life.1,2 Tocommunicate, speakers ac-cess information in long-termmemory, use executive
function,3 andprepareandexecuteamotor speechprogram.4,5
Therefore, neurocognitive function and motor speech pro-
cesses are interrelated in theproductionof speech.Neurocog-
nitive and speech functioning represent important domains
of investigation in patients with head and neck cancer (HNC)
because HNC and its treatment may alter speech6,7 and neu-
rocognitive functions.8,9 Research has indicated that neuro-
cognitive and speech problemsmay already be present in pa-
tients with HNC at baseline (ie, before treatment).10-13
Speechproblemsatbaselinehavebeendetectedusingself-
report questionnaires11 and through objective assessments
fromrecordedspeech.10Forexample,61%ofpatientswithHNC
reported that they had speech problems at baseline, with
greater difficulties in oral and oropharyngeal cancer relative
to laryngealandhypopharyngeal cancer.11Usingobjectivemea-
sures from recorded speech, abnormal intelligibility, nasal-
ity, and articulationwere found in 17% to 37%of the patients,
with oral cavity tumor cases scoring more poorly than oro-
pharyngeal tumor cases.10 Both self-reported and objective
measuresof speech impairmentcorrelatedwithpatients’ emo-
tional distress or perceived quality of life.10,11
Regardingneurocognitive functioning,muchless isknown.
Todate, fewstudies12-14have reported theprevalenceofneuro-
cognitive impairment (ie, clinically relevant deficits compared
withanage-andeducation-adjustednormativesample)asmea-
sured objectively before treatment among patients with HNC.
These studies found between 21% and 36% neurocognitive
impairment12,14 using several neuropsychological tests, with
about55%using theMontrealCognitiveAssessment (MoCA).13
Besidesdecreasingqualityof life,ahighprevalenceofneurocog-
nitive impairmentamongthispopulationbefore treatmentmay
complicate patient-clinician interaction and alter treatment
adherence.13 These factors emphasize thatbetter characteriza-
tion of pretreatment neurocognitive impairment is critical.
The baseline neurocognitive and speech deficits observed
inthispopulationmayhavedifferentandmutualetiologies.Cog-
nitivedeficitsoriginateatthelevelofthecentralnervoussystem,
but their etiologicalmechanismremainsunclear.12 In contrast,
motor speechdeficits areassociatedwithdamage to theorgans
andmuscles involved in speaking (eg, speechproblems are as-
sociatedwith tumor location11).However, speakingnotonly in-
volvesperipheralmotor function, including thevocal tract and
speech organs, but also engages multiple cognitive processes,
such as long-termmemory access4,5 and executive function.3
Beingable to communicate is an importantpredictorofquality
of life.1,2 Given that both speech andneurocognitive functions
mayalreadybeaffectedbefore treatment inpatientswithHNC,
examining these functions in one study sample provides valu-
able informationabout thispopulation.Todate,nostudyhasre-
portedonneurocognitive andspeech functioningbefore treat-
ment in the same group of patients.
Thepresentstudyfocusedonneurocognitivefunctioningand
speech before treatment using prospective data from a large
samplecollectedinanationwide,multicentersetting(Netherlands
Quality of Life and Biomedical Cohort Study in Head andNeck
Cancer [NET-QUBIC]project). First,wedocumentedneurocog-
nitivefunctioningasmeasuredobjectivelyandsubjectivelyinpa-
tientswithHNCbeforetreatment.Second,weinvestigateddemo-
graphic,behavioral,anddisease-relatedfeaturesassociatedwith
lowneurocognitive functioning inpatientswithHNC.Third,we
characterized for the first time to date the association between
neurocognitive and speech functioning in this population.
Methods
Patients
This research was part of a large, ongoing prospective cohort
studyinvestigating long-termqualityof life inpatientswithHNC
and their caregivers (NET-QUBIC study [https://researchers
.kubusproject.nl/general-information]). For thepresent analy-
ses, baselinedata (collectedbefore the start of treatment)were
used from the first data release, which included 254 newly
diagnosed patients with HNC. Clinical and demographic char-
acteristics, alcohol consumption, andsmokingstatuswerecol-
lected via self-report questionnaires andmedical records. The
characteristics of this group of patients are listed in theTable.
Patientswere recruited from8hospitals indifferent regions
in the Netherlands (Radboud University Medical Center,
Nijmegen; Amsterdam UMC, Amsterdam; University Medical
Center, Utrecht; UniversityMedical Centre Groningen, Gronin-
gen; Erasmus MC, Rotterdam; Rijnstate Hospital, Arnhem;
Noordwest Ziekenhuisgroep, Alkmaar; andMedisch Centrum,
Leeuwarden). Patientsmeeting the following inclusion criteria
were invited toparticipate: 18yearsorolder; able towrite, read,
andspeakDutchfluently;newlydiagnosedwithHNC(toincrease
homogeneity,restrictedtolarynx,hypopharynx,oropharynx,oral
cavity, and neck metastasis of unknown primary tumor with
provensquamouscellhistology [all stages]); andpreviouslyun-
treatedandcurrentlyplannedtreatmentwithcurative intentac-
cording to standard treatment guidelines, including surgery,
radiotherapy,and/orsystemicantineoplastic therapy.Exclusion
criteria were nasopharyngeal or skin cancers (due to their low
occurrence), tumors of the salivary glands, lymphoma thyroid
cancer, or severe psychiatric comorbidities (eg, schizophrenia,
Korsakoff syndrome,andseveredementia).Comorbidityscores
Key Points
Question What is pretreatment neurocognitive function in
patients with head and neck cancer and what is the association
between neurocognitive and speech functioning?
Findings In a cohort study of 254 newly diagnosed patients with
head and neck cancer, pretreatment objective neurocognitive
measures indicated 12.3% to 26.2%mild to moderate impairment
and 4.7% to 15.0%moderate to severe impairment. Self-perceived
neurocognitive functioning was significantly associated with
speech function.
Meaning Results of this study suggest that pretreatment
neurocognitive impairment is frequently present in patients with
head and neck cancer, and low self-perceived neurocognitive and
speech functioningmay alter communicative participation and
perceived quality of life.
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weredefinedaccording to theAdultComorbidityEvaluation27
(ACE-27).15Allparticipatingpatientssignedaninformedconsent.
Ethicalapprovalwasobtainedbythecoordinatingcenter (Medi-
calEthicalCommitteeVrijeUMC),andlocalapprovalwasobtained
foreachindividualcenter (amoredetailedexplanationaboutthe
procedure and recruitment has beenpreviously published16).
Assessments
Assessments were conducted at the hospital and/or the pa-
tient’s home by trained assessors. Cognitive assessment in-
cluded the Trail Making Test17 (TMT) parts A and B, the Hop-
kins Verbal Learning Test18 (HVLT), and letter fluency (a
detailed description of these tests has been previously
published19). Variables of interest in the present study were
TMT-A (ameasure of psychomotor speed), TMT-B (ameasure
of executive function and attentional control), delayed recall
(a measure of verbal long-termmemory) from the HVLT, and
letter fluency (ameasureofverbal fluency thatdependson lin-
guistic, motor, and executive processes20).
As patient-reported outcome measures, the Cognitive
Failures Questionnaire21 (CFQ) was used as a measure of self-
perceivedneurocognitivefunctioning.TheCFQisaquestionnaire
aboutfailures inperception,attention,memory,andmotorfunc-
tion (eg, “Doyoubump intopeople?”and“Doyou findyou for-
getpeople’snames?”).TheSpeechHandicapIndex22 (SHI)ques-
tionnairewasadministeredasameasureofself-perceivedspeech
functioning, with questions about speech problems (eg, “My
speechmakes itdifficult forpeople tounderstandme”and“The
intelligibilityisunpredictable”).TheSHIisavalid,reliablespeech-
specificquality-of-lifequestionnaire thathelps identify thena-
ture andseverityof theproblemsexperiencedbypatientswith
HNC.22A total SHIcanbecalculated ranging from0to120,with
higher scores indicatingmore speechproblemsandwitha cut-
off value of 6 being able to identify patients with speech prob-
lems in daily life. In addition, 2 subscales can be derived that
reflect psychosocial function and speech function.
Statistical Analysis
Although 254 patients met the inclusion and exclusion crite-
ria, not all patients completed all of the neuropsychological
tests or the self-report questionnaires (mainly due to logistic
reasonsor thepatients’ ownwithdrawal fromparticipation for
that part because patients could choose in which parts of the
NET-QUBICstudy theywanted toparticipate).Missingdata for
each individual testwere identified, and for eachanalysis only
completed cases at the analysis-specific level were included.
For all results, we report the sample size onwhich each of the
statistical tests was based.
Available normative data were used to convert the pa-
tients’ results on the neuropsychological tests into standard-
ized T scores (mean [SD], 50 [10]), adjusted for age, sex, and
education (HVLT18;TMT17; andverbal fluency, lettersB,D, and
H, norms derived from own databases). Patients for whom
demographic information was unknown were excluded. The
proportions of patients performing more than 1 SD andmore
than2SDsbelow the age-, sex-, andeducation-adjustednorm
werequantified.Neurocognitive impairmentwas classified as
mild to moderate (T score, 30-39 [ie, 1-2 SDs below the nor-
mative mean]), moderate to severe (T score, ≤29 [ie, >2 SDs
below the normativemean]), or unimpaired (T score, >39 [ie,
<1 SDbelow thenormativemean]). For theCFQ, cutoff values
were used to categorize the scores as very low (≤9), low (10-
20), average (21-43), high (44-54), or veryhigh (≥55).23 For the
SHI, apreviously established cutoff valueof6wasused.22The
association between objectively measured and patient-
reportedneurocognitive functionwasassessedwith theSpear-
man rank correlation coefficient (because the assumptions of
linearity and homoscedasticity as indicated by a Breusch-
Table. Demographic and Clinical Characteristics of Patients
for the Complete Data Set and Restricted to the Set of Patients
Who Completed All Patient-Reported OutcomeMeasures
and Neurocognitive Tests
Variable
No. (%)
Complete
Data Set
(N = 254)
Completed
All Tests
(n = 162)
Sex distribution, No. (%)
Men 182 (71.7) 116 (71.6)
Women 72 (28.3) 46 (28.4)
Education
Primary (6 y) 13 (5.1) 7 (4.3)
Lower or preparatory vocational (9 y) 53 (20.9) 38 (23.5)
Intermediary general secondary (10 y) 33 (13.0) 25 (15.4)
Senior general secondary (11 y) 40 (15.7) 29 (17.9)
Higher general secondary (15 y) 23 (9.1) 19 (11.7)
Higher professional (16 y) 38 (15.0) 30 (18.5)
University (18 y) 16 (6.3) 14 (8.6)
Missing 38 (15.0) 0
Literacy
Excellent (mother tongue) 173 (68.1) 134 (82.7)
Good 40 (15.7) 26 (16.0)
Average 4 (1.6) 2 (1.2)
Missing 37 (14.6) 0
Tumor stage
I 57 (22.4) 42 (25.9)
II 39 (15.4) 23 (14.2)
III 51 (20.1) 31 (19.1)
IVA 96 (37.8) 62 (38.3)
IVB 10 (3.9) 4 (2.5)
IVC 1 (0.4) 0
Tumor site
Larynx 66 (26.0) 40 (24.7)
Hypopharynx 23 (9.1) 14 (8.6)
Oropharynx 89 (35.0) 57 (35.2)
Oral cavity 72 (28.3) 47 (29.0)
Unknown 4 (1.6) 4 (2.5)
Comorbidity score
Severe 38 (15.0) 27 (16.7)
Moderate 40 (15.7) 26 (16.0)
Mild 87 (34.3) 47 (29.0)
No comorbidity 72 (28.3) 55 (34.0)
Missing 17 (6.7) 7 (4.3)
Smoking status
Never 24 (9.4) 16 (9.9)
Current 67 (26.4) 49 (30.2)
Former 118 (46.5) 90 (55.6)
Missing 45 (17.7) 7 (4.3)
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Pagan test were not met) for each neurocognitive test of in-
terest separately. The 95% CIs were computed via bootstrap-
ping (1000 replicates). The association between patient-
reported neurocognitive and speech functions was also
assessed in a similar fashion (for the total SHI, psychosocial
and speech function subscales separately). Finally, a linear re-
gressionwasused to assess the relative contributionof behav-
ioral (ie, alcohol consumption [continuous]) and disease-
related factors (ie, tumor stage, transformed into an ordinal
variable from 1 to 4, corresponding to stages I, II, III, and IVA,
IVB, and IVC), as well as their interaction with neurocogni-
tive functioning.Forobjectivemeasures, standardizedTscores
were used (ie, already corrected for age, sex, and education).
For patient-reported neurocognitive functioning, demo-
graphic variables (ie, age [continuous], sex [women as the
reference], and education [transformed into an ordinal vari-
able]) were also entered. All analyses were conducted in R
(The R Foundation),24 R base library, and RVAideMemoire
(CRAN [cran.r-project.org]) for computing 95% CIs of Spear-
man rank correlation coefficients. This study was preregis-
tered, and the preregistration is available in Supplement 1.
Results
Thecharacteristics of 254newlydiagnosedpatientswithHNC
are summarized in the Table. Participants were predomi-
nantlymale (182patients [71.7%]), and themean (SD) andme-
dian agewas62 (10) years (range, 37-85years), similar to other
studies.9,12,13,25 Most of the participants had stage IVA cancer
(37.8% [96 of 254]) and oropharyngeal cancer (35.0% [89 of
254]). Current alcohol consumption (total number of glasses
ofbeer,wine, andspiritsperweek) ranged from0to 140 (mean
[SD], 17 [20];median, 12).The response rate ranged from81.9%
(208 of 254) to 84.6% (215 of 254).
Whencomparingthedemographicandclinicalvariablesbe-
tweenpatientswhocompletedall tests vspatientswhodidnot
complete1ormoretests (summarized intheTable),noclinically
meaningful differenceswere found for age (mean,62.7 vs60.9
years, respectively), sexdistribution,education, literacy, tumor
stageand tumor site, or smoking status.Thedistributionof co-
morbidity scores did differ between the 2 groups. Those who
completed all assessmentsmoreoftenhad severe comorbidity
scoresornocomorbidity (17.4%severe, 16.8%moderate, 30.3%
mild,and35.5%none) relative to thosewhodidnotcompleteall
tests (13.4% severe, 17.1% moderate, 48.8% mild, and 20.7%
none).Twenty-eightpatientsdidnotcomplete theCFQandthe
SHI, but they completed all objective neurocognitive tests. No
differenceswerefoundinthescoresbetweenthe2groupsforany
test (all 95%CIsoverlapwithzero). Thirty-twopatientsdidnot
completeanyoftheobjectiveneurocognitivetests,buttheycom-
pleted both theCFQand the SHI.Nodifferenceswere found in
thescoresbetween the2groups (all 95%CIsoverlapwithzero).
As shown inFigure 1,moderate to severe impairmentwas
found in15.0%(32of214)of thepatients indelayedrecall,6.0%
(13 of 215) in letter fluency, 4.7% (10 of 212) in psychomotor
speed (TMT-A), and 5.7% (12 of 211) in executive functioning
(TMT-B).Mild tomoderate impairmentwas found in26.2%(56
of 214) of the patients in delayed recall, 24.2% (52 of 215) in
letter fluency, 12.3% (26 of 212) in psychomotor speed, and
20.4% (43 of 211) in executive functioning.
Figure 2 summarizes the patients’ self-reported cogni-
tive functioning (n = 208) and speech (n = 209) overall andby
tumor site. For the CFQ, 7.2% (15 of 208) of the patients re-
ported experiencing above-average failure; for the total SHI,
42.6% (89of 209) of the patients scored in the impaired range
for self-perceived speechproblems (ie, above the cutoff value
of 6).
Patient-reported and objective neurocognitive function-
ing was not associated with any variable (demographic, be-
havioral, or disease related): the models’ adjusted R2 values
were −0.006 for the CFQ, 0.025 for the SHI, −0.016 for de-
layed recall, −0.018 for letter fluency, 0.026 for psychomotor
speed, and −0.003 for executive functioning). Furthermore,
no significant associations were found in regression models
with additional variables of literacy, tumor site, comorbidity
score, andsmokingstatus: themodels’ adjustedR2valueswere
−0.035 for the CFQ, 0.116 for the SHI, −0.052 for delayed re-
call,0.034 for letter fluency,0.068forpsychomotor speed,and
−0.051 for executive functioning). The results of these mod-
els are summarized in eTables 1, 2, 3, and 4 in Supplement 2.
Objective and patient-reported neurocognitivemeasures
did not correlate significantly (all Spearman rank correlation
coefficientswerebetween−0.026and0.155, and95%CIsover-
lappedwithzeroexcept forTMT-A[95%CI,0.009-0.289]).Ob-
jective neurocognitive measures did not correlate signifi-
cantly with patient-reported speech outcome (all Spearman
rankcorrelationcoefficientswerebetween0.124and0.172,and
95%CIsoverlappedwithzeroexcept forTMT-B [95%CI,0.018-
0.321]). Patient-reportedneurocognitive functioningwas sig-
nificantly correlatedwith speech functioning (total SHI),with
a small effect size (ρ = 0.266; 95% CI, 0.126-0.400) (n = 195),
as shown in Figure 3 (also by tumor site). When the analyses
were restricted to the group that completed all tests (n = 162),
the exact sameassociationwas observed (ρ = 0.266). The SHI
Figure 1. Rate of Neurocognitive Impairment
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Patients scoring in themoderate to severe, mild to moderate, and unimpaired
range for delayed recall (from the Hopkins Verbal Learning Test), letter fluency
and psychomotor speed (from the Trail Making Test Part A), and executive
functioning (from the Trail Making Test Part B).
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subscales were also significantly correlated with patient-
reportedneurocognitive functioning (ρ = 0.245;95%CI,0.110-
0.374 for psychosocial function and ρ = 0.250; 95%CI, 0.116-
0.390 for speech function).However,withboth SHI subscales
as variables in a regression model of patient-reported neuro-
cognitive functioning, only the psychosocial function sub-
scalewas significant (psychosocial unstandardizedβ = 0.409,
t = 2.262; speech unstandardized β = −0.025, t = −0.194; ad-
justed R2 = 0.064).
Discussion
Using prospective data from a large sample collected
nationwide, the present study documented the prevalence
of neurocognitive and speech impairment before treatment
among patients newly diagnosed as having HNC. Moreover,
we report for the first time to our knowledge an association
between patient-reported neurocognitive and speech
Figure 3. Association Between Self-perceived Neurocognitive and Speech Functioning
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Figure 2. Patient-Reported Neurocognitive and Speech Functioning
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functioning and objectively measured neurocognitive
functioning.
Regardingspeech, almosthalfof thepatients reportedself-
perceivedspeech inthe impairedrange.Thisprevalence is simi-
lar towhathasbeenpreviously reported.11 Self-perceivedneu-
rocognitive failure was observed in a small subgroup of the
patients.
The prevalence of neurocognitive impairment we report
herein is similar to or slightly higher than that previously re-
portedusingcomparableneuropsychological tests,12,14withad-
ditional similarity in age, sex, and education between the
samples. However, the sample size ismore than 3 times larger
in our study, and our data were collected in a multicenter set-
ting. Furthermore, the prevalencewe report is lower than that
previously reported using the MoCA,13 with which more than
half of the patients were found to havemild cognitive impair-
ment. However, the MoCA has both a lower sensitivity and a
lowerspecificity thantheneuropsychological testsweused.26,27
In addition, the MoCA has limited adjustment for education
level.27 These 2 factors could explain thediscrepancybetween
our results and the findings based on that assessment.
The rates of severe to moderate impairment we observed
(4.7%-15.0%)arehigherthanwhatcanbeexpectedinthehealthy
population (inwhich by definition 2.3%of the population per-
forms ≥2 SDs below thenormativemean). Therefore, there is a
substantial subgroup of patients with HNC who are seen with
moderate to severe cognitive impairment already at baseline,
which could not be explained by demographic variables, such
asage, sex,andeducation,orbyalcoholconsumptionordisease
stage(aswellasliteracy,tumorsite,comorbidityscore,andsmok-
ing status as summarized in eTables 1, 2, 3, and 4 in Supple-
ment 2). Understanding the reason why this subgroup is seen
withneurocognitive impairmentbefore thestartof treatment is
important because treatments may trigger cerebrovascular
disease28andconsequently influenceneurocognitive function.
Asmentionedpreviously, it remainsanopenquestionwhether
theneurocognitive impairment iscausedbybiologicalprocesses
triggeredbythecancerand/orbyrisk factors thatalterbothcog-
nitive functioningandthepathology itself.12Forexample,Bond
etal12 foundanassociationbetweensmokingandalcoholabuse
on theonehandandbetween smoking andglobal neurocogni-
tive deficit on the other hand. However, the association with
alcohol abuse was not significant at the level of the individual
neurocognitive measures. In our sample, performance on the
neuropsychologicalmeasurescouldnotbeexplainedbyalcohol
consumption. Additional large-scale studies focusing on this
question are needed. Longitudinal studies on neurocognitive
changes after treatment, enabling comparison across different
treatment types,mayalsohelpelucidate thisquestionbecause
surgeryalone isexpectedtohaveasmaller influenceonthecen-
tral nervous system than chemotherapy or radiotherapy.
Limitations
Our study has some limitations.We did not include objective
measuresof speech functioning,but theyarenecessary for fur-
therunderstandingwhat alters apatient’s communicativepar-
ticipation. In addition, we did not have performance validity
measures that would enhance the interpretation of the neu-
ropsychological tests (eg, inhelpingexclude thepossibility that
lowperformanceon theneuropsychological testswasnotdue
to a lack of effort put forth by the individuals when perform-
ing the tests). Our study also lacks specific control data, mak-
ing it more difficult to interpret the results in light of risk fac-
tors for neurocognitive decline.
Conclusions
Understandingimpairmentinneurocognitivefunctioningatbase-
line,aswellasinrelationtospeechfunction, is importantnotonly
in itself (eg, for patient counseling and education and for treat-
ment decision making) but also for understanding treatment-
relatedchanges.Previousresearchexaminingthedeclineinneu-
rocognitivefunctionduetocancertherapyhasbeencriticizedfor
a lackofbaselinedata.29Our study is the first todate to system-
aticallyexamine theassociationbetweenpatient-reportedneu-
rocognitive functioning and patient-reported speech function-
ing already at baseline. We found an association, albeit weak,
betweenthepatient-reportedoutcomesofneurocognitive func-
tioningandspeech functioning.Thisassociationwasespecially
prominent among the patients with laryngeal cancer in our
sample.Thisgroupdoesnot shownotablyhigh ratesofpatient-
reportedcognitivefailure,buttherateofpatient-reportedspeech
impairmenthada larger spreadandgenerallyhighervalues.An
important question for future research iswhether this group is
particularlyvulnerable to treatment influences.Furthermore, it
ispossiblethat individualswhoexperiencemoreneurocognitive
failurealsohavemorecommunicationdifficulty.This interpre-
tationis furthersupportedbythefindinghereinthat thepsycho-
social function subscale of the SHI better explains the variance
in patient-reported neurocognitive functioning than does the
speechfunctionsubscaleoftheSHI.Overall, thedatasuggestthat
patient-reportedneurocognitiveandspeechfunctioningdodis-
sociatebutmay interactat the levelofdaily life situations, shap-
ingthepatients’perceptionoftheir functioning.Thisassociation
merits further investigationbecause itmayhold importantclues
tounderstandingpatient-clinician interactionaswell as thepa-
tients’perceivedcommunicativeparticipationandqualityoflife.30
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